New Tools for Early Cancer Detection in Primary Care
A Primer on Blood-Based Multi-Cancer Screening
Cell-free DNA analysis in current cancer clinical trials: a review.
Cisneros-Villanueva M, et al. Br J Cancer. 2022;126(3):391-400.
Projected reductions in absolute cancer–related deaths from diagnosing cancers before metastasis, 2006–2015.
Clarke CA, et al. Cancer Epidemiol Biomarkers Prev. 2020;29(5):895-902.
Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?
Duffy MJ, et al. Clin Chem Lab Med. 2021;59(8):1353-1361.
New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening.
Hackshaw A, et al. Cancer Cell. 2022;40(2):109-113
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.
Klein EA, et al. Ann Oncol. 2021;32(9):1167-1177.
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.
Liu MC, et al. Ann Oncol. 2020;31(6):745-759.
The PATHFINDER Study: assessment of the implementation of an investigational multi-cancer early detection test into clinical practice.
Nadauld LD, et al. Cancers (Basel). 2021;13(14):3501.
Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice.
Trevethan R. Front Public Health. 2017;5.
Liquid biopsies come of age: towards implementation of circulating tumour DNA.
Wan JCM, et al. Nat Rev Cancer. 2017;17(4):223-238.
Guidelines
US Preventive Services Task Force. Published Recommendations for Cancer.
A and B Recommendations
Clinician Resources
Prevent Cancer Foundation.
Multi-cancer early detection coverage and legislation.
Surveillance, Epidemiology, and End Results (SEER) *Explorer
An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute, Division of Cancer Control and Population Sciences.
Galleri Test Website
Menlo Park, CA: Grail LLC.
